194 related articles for article (PubMed ID: 36451822)
1. The Effect of immunotherapy on oligometastatic non-small cell lung cancer patients by sites of metastasis.
Ma JC; Zhang JX; Wang F; Yu J; Chen D
Front Immunol; 2022; 13():1039157. PubMed ID: 36451822
[TBL] [Abstract][Full Text] [Related]
2. Long-term outcomes in radically treated synchronous vs. metachronous oligometastatic non-small-cell lung cancer.
Fleckenstein J; Petroff A; Schäfers HJ; Wehler T; Schöpe J; Rübe C
BMC Cancer; 2016 Jun; 16():348. PubMed ID: 27255302
[TBL] [Abstract][Full Text] [Related]
3. Survival Impact of Aggressive Treatment and PD-L1 Expression in Oligometastatic NSCLC.
Gauvin C; Krishnan V; Kaci I; Tran-Thanh D; Bédard K; Albadine R; Leduc C; Gaboury L; Blais N; Tehfe M; Routy B; Florescu M
Curr Oncol; 2021 Jan; 28(1):593-605. PubMed ID: 33498159
[TBL] [Abstract][Full Text] [Related]
4. [Real-world study on the efficacy and prognostic predictive biomarker of patients with metastatic non-small cell lung cancer treated with programmed death-1/programmed death ligand 1 inhibitors].
Zhu WJ; Zhu HH; Liu YT; Lin L; Xing PY; Hao XZ; Cong MH; Wang HY; Wang Y; Li JL; Feng Y; Hu XS
Zhonghua Zhong Liu Za Zhi; 2022 May; 44(5):416-424. PubMed ID: 35615798
[No Abstract] [Full Text] [Related]
5. Consolidative Local Ablative Therapy Improves the Survival of Patients With Synchronous Oligometastatic NSCLC Harboring EGFR Activating Mutation Treated With First-Line EGFR-TKIs.
Xu Q; Zhou F; Liu H; Jiang T; Li X; Xu Y; Zhou C
J Thorac Oncol; 2018 Sep; 13(9):1383-1392. PubMed ID: 29852232
[TBL] [Abstract][Full Text] [Related]
6. Improved Overall Survival With Comprehensive Local Consolidative Therapy in Synchronous Oligometastatic Non-Small-Cell Lung Cancer.
Mitchell KG; Farooqi A; Ludmir EB; Corsini EM; Zhang J; Sepesi B; Vaporciyan AA; Swisher SG; Heymach JV; Zhang J; Gomez DR; Antonoff MB
Clin Lung Cancer; 2020 Jan; 21(1):37-46.e7. PubMed ID: 31447303
[TBL] [Abstract][Full Text] [Related]
7. A cost-effectiveness analysis of consolidative local therapy in oligometastatic non-squamous non-small cell lung cancer (NSCLC).
Panje CM; Dedes KJ; Matter-Walstra K; Schwenkglenks M; Gautschi O; Siano M; Aebersold DM; Plasswilm L; Lupatsch JE;
Radiother Oncol; 2018 Nov; 129(2):257-263. PubMed ID: 30104008
[TBL] [Abstract][Full Text] [Related]
8. Overall survival according to immunotherapy and radiation treatment for metastatic non-small-cell lung cancer: a National Cancer Database analysis.
Foster CC; Sher DJ; Rusthoven CG; Verma V; Spiotto MT; Weichselbaum RR; Koshy M
Radiat Oncol; 2019 Jan; 14(1):18. PubMed ID: 30691492
[TBL] [Abstract][Full Text] [Related]
9. Radiotherapy improves the survival of patients with stage IV NSCLC: A propensity score matched analysis of the SEER database.
Zhang R; Li P; Li Q; Qiao Y; Xu T; Ruan P; Song Q; Fu Z
Cancer Med; 2018 Oct; 7(10):5015-5026. PubMed ID: 30239162
[TBL] [Abstract][Full Text] [Related]
10. Should aggressive thoracic therapy be performed in patients with synchronous oligometastatic non-small cell lung cancer? A meta-analysis.
Li D; Zhu X; Wang H; Qiu M; Li N
J Thorac Dis; 2017 Feb; 9(2):310-317. PubMed ID: 28275479
[TBL] [Abstract][Full Text] [Related]
11. A risk stratification scheme for synchronous oligometastatic non-small cell lung cancer developed by a multicentre analysis.
Spaggiari L; Bertolaccini L; Facciolo F; Gallina FT; Rea F; Schiavon M; Margaritora S; Congedo MT; Lucchi M; Ceccarelli I; Alloisio M; Bottoni E; Negri G; Carretta A; Cardillo G; Ricciardi S; Ruffini E; Costardi L; Muriana G; Viggiano D; Rusca M; Ventura L; Marulli G; De Palma A; Rosso L; Mendogni P; Crisci R; De Vico A; Maniscalco P; Tamburini N; Puma F; Ceccarelli S; Voltolini L; Bongiolatti S; Morelli A; Londero F
Lung Cancer; 2021 Apr; 154():29-35. PubMed ID: 33610120
[TBL] [Abstract][Full Text] [Related]
12. Might radiation therapy in addition to chemotherapy improve overall survival of patients with non-oligometastatic Stage IV non-small cell lung cancer?: Secondary analysis of two prospective studies.
Su S; Hu Y; Ouyang W; Ma Z; Li Q; Li H; Wang Y; Wang X; Li T; Li J; Chen M; Lu Y; Bai Y; He Z; Lu B
BMC Cancer; 2016 Nov; 16(1):908. PubMed ID: 27871270
[TBL] [Abstract][Full Text] [Related]
13. Is there an oligometastatic state in non-small cell lung cancer? A systematic review of the literature.
Ashworth A; Rodrigues G; Boldt G; Palma D
Lung Cancer; 2013 Nov; 82(2):197-203. PubMed ID: 24051084
[TBL] [Abstract][Full Text] [Related]
14. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
15. Prognostic factors of oligometastatic non-small cell lung cancer: a meta-analysis.
Li S; Zhu R; Li D; Li N; Zhu X
J Thorac Dis; 2018 Jun; 10(6):3701-3713. PubMed ID: 30069368
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of single-site radiotherapy plus PD-1 inhibitors vs PD-1 inhibitors for oligometastatic non-small cell lung cancer.
Wang P; Yin T; Zhao K; Yu J; Teng F
J Cancer Res Clin Oncol; 2022 May; 148(5):1253-1261. PubMed ID: 34812931
[TBL] [Abstract][Full Text] [Related]
17. Ablative Therapy for Oligometastatic Non-Small Cell Lung Cancer.
Juan O; Popat S
Clin Lung Cancer; 2017 Nov; 18(6):595-606. PubMed ID: 28377206
[TBL] [Abstract][Full Text] [Related]
18. Stereotactic radiosurgery with immunotherapy is associated with improved overall survival in patients with metastatic melanoma or non-small cell lung cancer: a National Cancer Database analysis.
Jiang JM; Kabarriti R; Brodin NP; Ohri N; Guha C; Kalnicki S; Garg M
Clin Transl Oncol; 2022 Jan; 24(1):104-111. PubMed ID: 34236616
[TBL] [Abstract][Full Text] [Related]
19. Predictive value of tumor mutational burden for immunotherapy in non-small cell lung cancer: A systematic review and meta-analysis.
Meng G; Liu X; Ma T; Lv D; Sun G
PLoS One; 2022; 17(2):e0263629. PubMed ID: 35113949
[TBL] [Abstract][Full Text] [Related]
20. Definitive primary therapy in patients presenting with oligometastatic non-small cell lung cancer.
Parikh RB; Cronin AM; Kozono DE; Oxnard GR; Mak RH; Jackman DM; Lo PC; Baldini EH; Johnson BE; Chen AB
Int J Radiat Oncol Biol Phys; 2014 Jul; 89(4):880-7. PubMed ID: 24867533
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]